Engineering of a stable retroviral gene delivery vector by directed evolution.

The lack of safe and effective delivery vectors continues to be a critical limitation facing human gene therapy. Viruses offer excellent efficiency but can be difficult and expensive to produce and purify. For example, the production and efficiency of murine leukemia virus (MLV) are limited by its inherent instability; the half-life of infectivity is 5-8 hours at 37 degrees C. In order to generate a stable MLV, we randomly mutated the virus genome and selected for infectivity after prolonged incubation at 37 degrees C. After seven rounds of incubation and infection, we isolated a pool of MLV variants with double the half-life of wild-type MLV. Remarkably, a single mutation in the viral protease (PR), G119E, was responsible for the enhanced stability. Saturation mutagenesis at residue 119 revealed variants with half-lives of approximately 24 hours at 37 degrees C. Double mutants combining the changes at position 119 of the PR and substitutions in the PR substrate-binding pocket exhibited half-lives of up to approximately 40 hours. MLV variants provided two- to fourfold higher viral titers and exhibited increased stability with various wild-type envelope proteins. The improved stability of the variant MLVs will provide more facile virus production and increased transduction efficiency.

[1]  A Wlodawer,et al.  Structural and biochemical studies of retroviral proteases. , 2000, Biochimica et biophysica acta.

[2]  A. Pinter,et al.  The nature of the association between the murine leukemia virus envelope proteins. , 1978, Virology.

[3]  G. Winter,et al.  Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. , 1996, Journal of molecular biology.

[4]  T Friedmann,et al.  Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  W. Stemmer,et al.  Breeding of retroviruses by DNA shuffling for improved stability and processing yields , 2000, Nature Biotechnology.

[6]  M L Yarmush,et al.  Large‐Scale Processing of Recombinant Retroviruses for Gene Therapy , 1999, Biotechnology progress.

[7]  R. Hosur,et al.  Effects of remote mutation on the autolysis of HIV-1 PR: X-ray and NMR investigations. , 2002, Biochemical and biophysical research communications.

[8]  Young Jik Kwon,et al.  Determination of Infectious Retrovirus Concentration from Colony-Forming Assay with Quantitative Analysis , 2003, Journal of Virology.

[9]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[10]  J. L. Le Doux,et al.  Kinetics of retrovirus production and decay. , 1999, Biotechnology and bioengineering.

[11]  E. Freire,et al.  The structural stability of the HIV-1 protease. , 1998, Journal of molecular biology.

[12]  I. Katoh,et al.  Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Rein,et al.  Macromolecular requirements for abrogation of Fv-1 restriction by murine leukemia viruses , 1980, Journal of virology.

[14]  C. Flexner.  HIV-protease inhibitors. , 1998, The New England journal of medicine.

[15]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[16]  W. Stemmer,et al.  Genome shuffling leads to rapid phenotypic improvement in bacteria , 2002, Nature.

[17]  R. Swanstrom,et al.  Synthesis, Assembly, and Processing of Viral Proteins , 1997 .

[18]  J. L. Raina,et al.  Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. , 1992, Virology.

[19]  J. Weissenbach,et al.  A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10 , 1993, Nature Genetics.

[20]  K. Ellem,et al.  The significance of controlled conditions in lentiviral vector titration and in the use of multiplicity of infection (MOI) for predicting gene transfer events , 2004, Genetic vaccines and therapy.

[21]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[22]  W. Anderson,et al.  Role of Variable Regions A and B in Receptor Binding Domain of Amphotropic Murine Leukemia Virus Envelope Protein , 1998, Journal of Virology.

[23]  I. Weber,et al.  Mutational Analysis of the Substrate Binding Pocket of Murine Leukemia Virus Protease and Comparison with Human Immunodeficiency Virus Proteases (*) , 1995, The Journal of Biological Chemistry.

[24]  B. Palsson,et al.  Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours , 1997, Journal of virology.

[25]  T. Friedmann,et al.  In Vitro Cell-Free Conversion of Noninfectious Moloney Retrovirus Particles to an Infectious Form by the Addition of the Vesicular Stomatitis Virus Surrogate Envelope G Protein , 1998, Journal of Virology.

[26]  F. Arnold.  Design by Directed Evolution , 1998 .

[27]  I. Weber.  Structural alignment of retroviral protease sequences. , 1989, Gene.

[28]  O. Merten.  State‐of‐the‐art of the production of retroviral vectors , 2004, The journal of gene medicine.

[29]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[30]  Inder M. Verma,et al.  Gene therapy: trials and tribulations , 2000, Nature Reviews Genetics.

[31]  William R. Taylor,et al.  A structural model for the retroviral proteases , 1987, Nature.

[32]  A. Kingsman,et al.  A transient three-plasmid expression system for the production of high titer retroviral vectors. , 1995, Nucleic acids research.